Related by context. All words. (Click for frequent words.) 87 Presents Preclinical Data 86 Clinical Trial Results 85 Drug Candidate 84 Anti Tumor Activity 84 Phase 2b Clinical Trial 83 Present Preclinical Data 82 Meets Primary Endpoint 81 Phase IIb Clinical Trial 81 Prolongs Survival 81 Anti Tumor 81 Phase 2b Trial 81 Completes Patient Enrollment 81 Preclinical Study 81 Antitumor Activity 80 Study Evaluating 80 Kinase Inhibitor 80 Completes Enrollment 80 Presents Positive 80 Phase 2a Trial 80 Well Tolerated 80 Novel Oral 80 Phase III Clinical Trial 80 Receives Orphan Drug Designation 80 Oral Fingolimod 80 Phase 2a Clinical Trial 79 Phase IIb Trial 79 II Clinical Trial 79 Anticancer Activity 79 Improves Survival 79 Patient Enrollment 79 Hsp# Inhibitor 79 Initiates Clinical Trial 78 Metastatic Melanoma 78 Files IND 78 Previously Treated 78 Novel Antibiotic 78 HCV Protease Inhibitor 78 Pooled Analysis 78 Phase 2b Study 78 Patients Treated With 78 Novel Mechanism 78 Initiates Clinical 78 Pharmacokinetic Study 78 Investigational Compound 78 Pivotal Study 77 Small Molecule 77 Pivotal Phase III 77 Phase III Trial 77 Survival Benefit 77 Mouse Model 77 RNAi Therapeutic 77 JAK2 Inhibitor 77 RNAi Therapeutics 77 Initiates Phase II 77 JAK Inhibitor 77 Statistically Significant 77 Combination Treatment 77 First Patient Enrolled 77 Submits NDA 77 Drug Shows Promise 77 Investigational Agent 77 FDA Accepts 77 Lupus Drug 77 Vaccine Adjuvant 77 Initiates Phase 77 Reports Preclinical Data 77 Investigational Drug 77 HDAC Inhibitor 77 Study Showed 77 Clinical Trial Evaluating 77 Demonstrates Efficacy 77 Study Demonstrates 76 Beneficial Effects 76 Clinical Trial Data 76 Demonstrates Positive 76 Collaborators Present 76 Initiates Enrollment 76 Is Well Tolerated 76 Phase III Trials 76 Immunomedics Announces 76 Initiate Phase 76 Nicotine Vaccine 76 Successfully Completes Phase 76 Granted Orphan Drug 76 Osteoporosis Treatment 76 Protease Inhibitor 76 Dose Ranging Study 76 Develop Novel 76 Advanced Melanoma 76 FDA Approvals 76 Novel Inhibitor 76 Orally Active 76 Pharmacyclics Announces 76 Shows Promising 76 Spectrum Pharmaceuticals Announces 76 Investigational Treatment 75 Initiates Phase III 75 Controlled Trial 75 Relapsing Multiple Sclerosis 75 Dendritic Cells 75 Tyrosine Kinase Inhibitor 75 IND Filing 75 Demonstrates Potent 75 Single Dose 75 Sangamo BioSciences Announces 75 Lung Cancer Drug 75 Sapacitabine 75 Phase IIa Clinical Trial 75 IND Application 75 Immune Responses 75 Combination REOLYSIN R 75 Demonstrates Significant 75 Demonstrates Potential 75 Presents Preclinical 75 NDA Submission 75 Receives Orphan Drug 75 Pivotal Phase 75 Therapeutic Potential 75 Receives Milestone Payment 75 Clinical Efficacy 75 Trial Evaluating 75 Double Blind Placebo 75 Patients Treated 75 Renal Cell Carcinoma 75 Monotherapy 75 Phase 1b Clinical Trial 75 First Patient Dosed 75 Significantly Improves 75 Transdermal Patch 75 Initiate Phase III 75 Antibody Drug Conjugate 75 Adjuvant Chemotherapy 75 Improves Outcomes 74 Collaborators Publish 74 Humanized Anti 74 Hormone Refractory Prostate Cancer 74 Cholesterol Lowering Drug 74 Announces Presentation 74 Treatment Regimen 74 Antiviral Activity 74 Lung Cancer Trial 74 Treatment Reduces 74 Multiple Myeloma Patients 74 Therapeutic Antibody 74 Late Breaker 74 Chronic Hepatitis C 74 Migraine Drug 74 Anticancer Drug 74 Shows Promise Against 74 Improved Survival 74 Monoclonal Antibody 74 Long Term Efficacy 74 Significantly Improved 74 MEK Inhibitor 74 Adjuvant Treatment 74 First Patient Treated 74 Osteoporosis Drug 74 Clinical Outcome 74 Demonstrated Significant 74 Adjunctive Therapy 74 Phase Ib Clinical Trial 74 Disease Modifying 74 Systemic Delivery 74 Randomized Phase 74 Severe Sepsis 74 Tezampanel 74 Oral Presentations 74 Patients Suffering 74 Epilepsy Drug 74 Initiate Clinical Trial 74 Novel Compound 74 Pulmonary Arterial Hypertension 74 Neoadjuvant Chemotherapy 74 Treatment Naïve 74 Treated Patients 74 Complicated Skin 74 Announces Poster Presentations 74 Controlled Study 74 Earns Milestone Payment 74 Mouse Models 74 Poster Presentations 74 Drug Resistant 74 Receives Approvable Letter 73 Pivotal Trial 73 Milestone Payment 73 Patent Covering 73 FDA Clears 73 Patients Receiving 73 Hematological Malignancies 73 Proves Effective 73 Prostate Cancer Patients 73 Pivotal Trials 73 Anticancer Agent 73 Regenerative Cells 73 FDA Okays 73 Telaprevir VX 73 Commences Phase 73 Gout Drug 73 Randomized Clinical Trial 73 Shows Efficacy 73 Nuvelo Announces 73 Abstract Accepted 73 Pegylated 73 Randomized Double Blind 73 Universal Flu Vaccine 73 Recombinant Human 73 Fungal Infections 73 Inhibits 73 Receptor Antagonist 73 Potent Antiviral Activity 73 Metastatic Renal Cell Carcinoma 73 Antiviral Drugs 73 Vaccine Candidate 73 Psoriasis Drug 73 Dose Escalation 73 Rheumatoid Arthritis Drug 73 Appears Safe 73 Romidepsin 73 PRN FDA Approves 73 Oral Calcitonin 73 Files Investigational 73 Advanced Renal Cell 73 Hematological Cancers 73 Low Dose 73 Licenses Novel 73 Meta Analysis 73 Investigational Oral 73 Phase III Clinical Trials 73 Randomized Trials 73 Resistant Hypertension 73 Receptor Agonist 73 Improve Survival 73 AnaSpec Introduces 73 Therapeutic Vaccine 73 Therapeutic Competitors Companies 73 Kinase Inhibitors 73 Myelodysplastic Syndromes 73 Shows Promise 73 Polymerase Inhibitor 73 Castration Resistant Prostate Cancer 73 Enrolls First 73 Proven Effective 73 Fewer Side Effects 73 Plus Ribavirin 73 Announces FDA Clearance 73 Newly Diagnosed Multiple Myeloma 73 Pharmacokinetics PK 73 Unfractionated Heparin 73 Biomarker Study 73 Diabetic Neuropathy 72 Elderly Patients 72 Targeted Therapies 72 Drug Combo 72 Inflammatory Arthritis 72 Refractory Hodgkin Lymphoma 72 Randomized Double Blind Placebo 72 Tumor Targeting 72 Drug Fails 72 Novel Therapeutic 72 Heart Failure Patients 72 Myeloma Patients 72 BiTE Antibody 72 Placebo Controlled Trial 72 HER2 Positive Breast Cancer 72 Aptamer 72 Initiates Dosing 72 Initiates Phase 2b 72 Announces Publication 72 Potent Inhibitor 72 Hypertensive Patients 72 Dose Finding 72 Synthetic Peptide 72 Relapsed Multiple Myeloma 72 Receives FDA Clearance 72 Rheumatoid Arthritis Patients 72 Solid Tumors 72 Aurora Kinase 72 Kidney Transplant Recipients 72 Adjuvant Therapy 72 Demonstrates Ability 72 Plaque Psoriasis 72 Diabetic Nephropathy 72 Preclinical Efficacy 72 Effectively Treats 72 AVI BioPharma Announces 72 Gene Variants 72 Antitumor 72 FOLOTYN ® 72 Infected Patients 72 Taro Receives 72 Statin Therapy 72 Vaccine Protects Against 72 Begins Dosing 72 Receives Fast Track 72 Advanced Prostate Cancer 72 Progenitor Cells 72 Antiangiogenic 72 Interferon Gamma 72 Cutaneous T 72 Initiates Clinical Trials 72 Topline Results 72 Tumor Growth 72 Treatment Resistant 72 Anti Inflammatory Drug 72 Submits IND 72 pralatrexate injection folate analogue 72 Data Suggest 72 Announces Initiation 72 Modulates 72 Phase 2a Study 72 Prostate Cancer Vaccine 72 Newly Diagnosed 72 Vitro Activity 72 Brentuximab Vedotin SGN 72 Autologous Stem Cell Transplantation 72 Nucleoside 72 Disease Progression 72 Preclinical Models 72 Vicriviroc 72 Confirmatory Phase 72 Interferon Beta 72 Kidney Transplant Patients 72 Vascular Disrupting Agent 72 Study Indicates 72 Glufosfamide 72 Topical Treatment 72 Treating Chronic 72 Inhaled Corticosteroids 72 Metastatic Prostate Cancer 72 Postmenopausal Women 72 Treatment Experienced 72 Mylan Receives Approval 72 Phospholipase A2 72 Significantly Reduced 71 Clinical Study Shows 71 Metastatic Colorectal Cancer 71 #nd EORTC NCI 71 Arthritis Drug 71 Intravenous Formulation 71 Combination Therapy 71 Novel Treatments 71 Flamel Technologies Announces 71 Therapy Improves 71 Successfully Treated 71 Cancer Cells 71 Oral Mucositis 71 Patients Enrolled 71 Trodusquemine MSI 71 Hypercholesterolemia 71 Attenuates 71 See CLINICAL PHARMACOLOGY 71 Advanced Ovarian Cancer 71 Expanded Indication 71 Bare Metal Stents 71 Therapeutic Efficacy 71 Fast Track Status 71 Anti CD# Antibody 71 Chemotherapeutic Agents 71 Versus Placebo 71 Immunomodulatory 71 Gene Mutation 71 Prospective Randomized 71 Test Detects 71 Antifungal 71 Anti Inflammatory 71 Rotavirus Vaccine 71 Cancer Stem Cells 71 Antigen Specific 71 Treatment Naive Patients 71 Efficacious 71 Gene Linked 71 Subgroup Analysis 71 Slow Progression 71 Generic Version 71 Pafuramidine 71 Induces 71 Hormone Receptor Positive 71 Bavituximab 71 Clinical Study 71 Previously Untreated 71 Completes Dosing 71 Anticancer Compound 71 Insulin Resistance 71 Efficacy Trial 71 Combo Therapy 71 Proteasome 71 Liposomal 71 Diabetic Patients 71 Pivotal Clinical Trial 71 Patents Covering 71 Chemotherapy Regimen 71 Atypical Antipsychotic 71 Significantly Reduces 71 Phase III Pivotal 71 Synta Announces 71 Schizophrenia Drug 71 Significant Improvement 71 Confirms Efficacy 71 Phase III Pivotal Trial 71 Genes Linked 71 DOR BioPharma Announces 71 Antisense Drug 71 PEGylated Fab fragment 71 Brain Metastases 71 Advanced Colorectal Cancer 71 Prodrug 71 Epidermal Growth Factor Receptor 71 Pediatric Patients 71 Relapsed Refractory 71 Factor Receptor 71 Gets FDA Clearance 71 Mimetics 71 Refractory Angina 71 pan HDAC inhibitor 71 Reveals Positive 71 Contrast Agents 70 Cholesterol Drug 70 NMDA Receptor 70 Cardiotoxicity 70 PKC# 70 Presents Positive Preclinical 70 Oral Formulation 70 Protein Linked 70 Inflammatory Diseases 70 Malaria Vaccine 70 Patients Undergoing 70 Localized Prostate Cancer 70 Personalized Immunotherapy 70 Bosutinib 70 Guidelines Recommend 70 Randomized Double blind 70 Shown Effective 70 Randomized Phase II 70 Inflammatory Disease 70 Inflammatory Markers 70 oral prodrug 70 Emerging Therapies 70 Overactive Bladder 70 Achieves Primary Endpoint 70 Desvenlafaxine Succinate 70 TO AVOID PREGNANCY WHILE 70 dependent kinase inhibitor 70 Announce License Agreement 70 Angiogenic 70 Demonstrates Sustained 70 Tumor Cells 70 Lowers Risk 70 Osteoporosis Drugs 70 Increased Risk 70 Molecular Diagnostic Test 70 Lupus Nephritis 70 Companion Diagnostic 70 Less Invasive 70 Autoimmune Disease 70 Dose Response 70 Liver Metastases 70 Therapeutic Vaccines 70 Randomised Trial 70 Safinamide 70 Schizophrenia Treatment 70 Neuroprotective Effects 70 Therapeutic Targets 70 Colorectal Cancer Patients 70 Autoimmune Diseases 70 Platelet Inhibition 70 Chronic Sinusitis 70 TNF Blockers 70 ISTODAX ® 70 Stem Cell Treatment 70 Aliskiren 70 Node Positive 70 Anti Angiogenic 70 Anthracycline 70 Postmenopausal Osteoporosis 70 Chronic Hepatitis B 70 Randomized Study 70 Osteoarthritis Patients 70 Cancer Therapies 70 Mg Usa 70 Commence Phase 70 Hepatocellular Carcinoma 70 Gene Variation 70 Preclinical Evaluation 70 R roscovitine CDK cyclin 70 Demonstrate Significant 70 Protein Involved 70 Tolerability 70 Kidney Function 70 Teva Provides Update 70 Breast Cancer Recurrence 70 TKB# 70 Cannabinoid 70 Advanced Pancreatic Cancer 70 Epratuzumab 70 Replacement Therapy 70 Human Monoclonal Antibody 70 Fondaparinux 70 Viral Infections 70 Immunotherapeutic 70 Bortezomib 70 Aflibercept 70 Effective Than 70 Lanthanum Carbonate 70 Tablet Formulation 70 Lung Cancers 70 Renal Cancer 70 Protease Inhibitors 70 Smooth Muscle 70 Prophylactic Treatment 70 Randomized Controlled Trials 70 Treating Heart Failure 70 Androgen Receptor 70 Cancer Treatments 70 Potentially Fatal 70 Positive Results 70 Drug Prevents 70 Projected Release Date 70 Anticancer Drugs 70 Commercialize Novel 69 Metabolic Efficiency 69 Researchers Identify 69 Elagolix 69 Cocaine Addiction 69 Significant Improvements 69 Gene Therapy Trial 69 CYT# potent vascular disrupting 69 Bone Metastases 69 Receives Patent 69 Protein Synthesis 69 Smallpox Vaccine 69 Knee Osteoarthritis 69 HER2 Positive 69 Ridaforolimus 69 Lung Tumors 69 Anti Clotting Drug 69 Gene Variant 69 Breast Cancer Cells 69 Gastrointestinal Disorders 69 Circulating Tumor Cells 69 Long Term Outcomes 69 Recurrent Breast Cancer 69 Secondary Hyperparathyroidism 69 Receive Milestone Payment 69 Diffuse Large B 69 Diabetic Neuropathic Pain 69 Anti Angiogenesis 69 Glaucoma Treatment 69 dasatinib Sprycel ® 69 Clinical Evaluation 69 non nucleoside inhibitor 69 Transdermal Delivery 69 Glatiramer Acetate 69 Medoxomil 69 Inhalation Solution 69 Sustained Efficacy 69 Preclinical Studies 69 Respiratory Virus 69 Melphalan 69 Methylnaltrexone 69 Blood Pressure Drug 69 Tumor Necrosis Factor 69 Pharmaceuticals Initiates 69 Cites Positive 69 Migraine Treatment 69 EntreMed Presents 69 Treatment Shows Promise 69 Achieves Milestone 69 FDA Clearance 69 Hepatic Encephalopathy 69 familial amyloidotic polyneuropathy FAP 69 Nasal Powder 69 Reduces Risk 69 Acute Ischemic Stroke 69 Immune Cell 69 Radiation Induced 69 Dose Ranging 69 Insulin Glargine 69 Anti Inflammatory Drugs 69 Immune Cells 69 Novel Anticancer 69 Submits Biologics License Application 69 Hepatitis C Treatment 69 Benign Prostatic Hyperplasia 69 AAG geldanamycin analog 69 Invasive Breast Cancer 69 Minimally Invasive Treatment 69 Inhaled Insulin 69 Obtains Exclusive License 69 R lenalidomide 69 Endothelial Cells 69 Metabolic Disorder 69 Sirolimus Eluting Stent 69 Hedgehog Pathway 69 Cell Transplants 69 Holds Promise 69 Phase IIa Trial 69 Study Confirms 69 Treatment Naïve Patients 69 FDA APPROVES 69 Skeletal Muscle 69 Breast Tumors 69 Signaling Pathway 69 Oncolytic 69 Study Evaluates 69 Selective Cardiac Myosin 69 ST Elevation Myocardial 69 Systemic Sclerosis 69 Nymox NX 69 Small Molecules 69 Critically Ill Patients 69 Liver Toxicity 69 Potent Anti 69 Agonist MABA program 69 VIVUS Announces 69 Placebo Controlled Study 69 CD# CEA 69 Eluting Stent 69 investigational humanized monoclonal antibody 69 Unresectable 69 Reduced Risk 69 Malignant Melanoma 69 siRNA Delivery 69 Metabolic Disease 69 Leukemia Cells 69 Randomized Placebo Controlled Trial 69 essential thrombocythemia ET 69 Chronic Myeloid Leukemia 69 Demonstrates Statistically Significant 69 Stent Restenosis 69 Suppresses 69 Avian Flu Vaccine 69 Virus Infection 69 Renal Function 69 Dose Escalation Study 69 Genes Involved 69 Completes Patient Enrolment 69 FDA Approves 69 Gastric Cancer 69 Patient Accrual 69 Xcytrin R 69 Colorectal Adenomas 69 Clostridium difficile Infection 69 Increased Mortality 69 Venous Thromboembolism 69 Study Shows Benefits 69 Acute Heart Failure 69 Integrase Inhibitor 69 Telik Announces 69 Guidelines Issued 69 Tyrosine Kinase Inhibitors 69 Chronic Lymphocytic Leukemia 69 Submits Response 69 Blood Thinner 69 Hemodialysis Patients 69 Novel Method 69 Shows Statistically Significant 69 Hepatitis C Infection 69 Antiplatelet 69 Levels Linked 69 fosbretabulin 69 Chemotherapy Improves 69 Aeolus Pharmaceuticals Announces 69 Asthma Treatment 69 Percutaneous Tibial Nerve Stimulation 69 Announce Initiation 69 PDUFA Date 69 Imaging Technique 68 Novel Anti Inflammatory 68 Files Patent Application 68 Protein Expression 68 Endometrial Cancer 68 Effective Treatments 68 Lung Cancer Patients 68 Inhaled Nitric Oxide 68 Myelofibrosis 68 vapreotide acetate 68 Voreloxin 68 Blinatumomab 68 Announces Positive 68 Cell Lymphoma 68 Combination Clinical Trial 68 Prostate Cancer Treatment 68 Vildagliptin 68 Faropenem 68 Drug Eluting 68 Antipsychotic 68 Peginterferon Alfa 2a 68 Tesetaxel 68 CYP#A# CYP#D# 68 Tigecycline 68 Renal Impairment 68 Lung Cancer Survival 68 sunitinib Sutent ® 68 Deforolimus 68 Capsules CII 68 Accelr8 Announces 68 Testosterone Gel 68 Novel Antibody 68 sarcoma melanoma 68 Romiplostim 68 Study Validates 68 ST Segment Elevation 68 Tumor Suppressor 68 Pharmacodynamics 68 Showed Significant 68 Liver Tumors 68 Successful Completion 68 Subtypes 68 Histone Deacetylase 68 platform HDL Mimetic 68 Announce Collaboration Agreement 68 Left Ventricular Hypertrophy 68 Receives Complete Response 68 orally administered inhibitor 68 5 Fluorouracil 68 Experimental Vaccine 68 Targeted Therapy 68 Testosterone Patch 68 Maribavir 68 Genetic Variation 68 Ofatumumab 68 Slows Progression 68 Cardiovascular Events 68 Placebo Controlled 68 Partial Onset Seizures 68 Study Proves 68 Improve Outcomes 68 HDAC Inhibitors 68 Antiviral Therapy 68 Albuferon TM 68 Supplemental Biologics License Application 68 Glucocorticoid 68 AASLD Meeting 68 Sustained Reduction 68 Randomized Clinical Trials 68 Stent Implantation 68 2 methoxyestradiol 68 Soft Tissue Sarcoma 68 Oral Presentation 68 Results Confirm 68 Non Invasive Treatment 68 Breast Cancer Patients 68 Parathyroid Hormone 68 Recombinant Protein 68 Resubmission 68 investigational oral inhibitor 68 Carboplatin Paclitaxel 68 Tumor Response 68 Employment Inducement Awards 68 Peginterferon 68 Newly Identified 68 Endovascular Treatment 68 Efficacy Results 68 Panzem R 68 Therapy Reduces 68 Chemokine Receptor 68 Develops Novel 68 Signaling Pathways 68 Cardiovascular Outcomes 68 Allogeneic 68 Monoclonal Antibodies 68 imatinib Gleevec ® 68 Key Milestones 68 Viral Suppression 68 Vaccine Shows Promise 68 Randomized Controlled Trial 68 Myocardial Ischemia 68 Multiple Ascending Dose 68 Safety Tolerability 68 Sirolimus Eluting 68 Kidney Transplants 68 Rigel R# 68 Helps Identify 68 Oral Spray 68 Cethromycin 68 Hepatitis C Virus 68 Therapy Evaluation 68 Novel Compounds 68 Reduces Pain 68 Novel Vaccine 68 SPRYCEL ® 68 Proc Am Soc 68 Prove Effective 68 Prognostic Value 68 Chemotherapy Induced Anemia 68 Naturally Occurring 68 Brain Cells 68 Cervical Cancer Vaccine 68 Diagnostic Criteria 68 Hospital Acquired Pneumonia 68 Prognostic Significance 68 Chronic Renal Failure 68 Breast Cancer Treatment 68 Biologic Therapy 68 Conjugate 68 DNA Methylation 68 Fixed Dose 68 Abstract Number 68 Anemia Drug 68 Ebola Vaccine 68 Cancer Vaccines 68 Tumor Progression 68 Patient Enrolment 68 Dual Antiplatelet Therapy 68 Study Shows Promise 68 Mg Uk 68 Contrast Agent 68 Controlled Clinical Trial 68 Pivotal Phase II 68 EGFR HER2 68 Increases Risk 68 Orthop Surg 68 ACE Inhibitors 68 Viral Load 68 Long Term Survival 68 Pralatrexate 68 Beta Blocker 68 Therapy Shows Promise 68 Acute Attacks 68 PROSTASCINT R 68 Crit Rev 68 Diuretic 68 Generic Versions 68 Scientists Identify 68 Patent Issued 68 Ovarian Cancer Patients 68 BioElectronics Announces 68 Molecular Mechanism 68 Male Contraceptive 68 Virus Linked 68 lexidronam injection 68 Neural Stem Cells 68 Cardiomyocytes 68 Significant Reduction 68 Genes Identified 68 Oral Insulin 68 Submits Supplemental 68 ALN TTR 68 Milestone Payments 68 Ranolazine 68 Poniard Pharmaceuticals Announces 67 Atypical Antipsychotics 67 Adenoviral 67 Taxane 67 Tuberculosis Vaccine 67 Protein Kinase 67 Non Responders 67 Oral Laquinimod 67 CYPHER R Sirolimus Eluting 67 Relapsing Remitting Multiple Sclerosis 67 Peginterferon Alfa 2b 67 Advanced Solid Tumors 67 Non Inferiority 67 Nanoemulsion 67 Receptor Antagonists 67 AACR Meeting 67 mGluR5 negative 67 Issued Patent 67 Cervical Dysplasia 67 Analogs 67 targeting CD# 67 Novel Small Molecule 67 Drug Formulation 67 THERAPEUTICS 67 ALN HPN 67 Ischemic Stroke 67 Mycophenolate Mofetil 67 Disease IBD 67 Crofelemer budesonide foam 67 Anticoagulant 67 Genetic Markers 67 Prostate Tumors 67 Bucindolol 67 Peer Reviewed Journal 67 Antiplatelet Therapy 67 Naive Patients 67 Adipose Derived Stem Cells 67 pan histone deacetylase 67 Ozarelix 67 NICE Recommends 67 Diagnostic Tests 67 Dry Powder Inhaler 67 Microplasmin 67 Immunosuppression 67 Morpholino 67 Risk Stratification 67 Bioartificial Liver 67 Severe Asthma 67 Cholesterol Drugs 67 Hedgehog Pathway Inhibitor 67 Erectile Dysfunction Drug 67 Left Ventricular 67 Unstable Angina 67 FDA Approves Drug 67 Artery Disease 67 Enlarged Prostate 67 Malignant Glioma 67 Serious Infections 67 Induction Therapy 67 Autoimmune Disorders 67 Oral Cladribine 67 Begin Clinical Trials 67 Bazedoxifene 67 Intracranial Aneurysms 67 Prognostic Factors 67 Gene Silencing 67 Sagent Pharmaceuticals Announces 67 Prostate Cancer Cells 67 Coronary Arteries 67 Monoclonal 67 GRAS Status 67 Significantly Increases 67 Radiofrequency Ablation 67 Heart Transplant Recipients 67 candidates Azedra 67 Primary Endpoint 67 Hepatitis C Patients 67 Adenoma 67 Zoledronic Acid 67 Transcription Factor 67 Oligonucleotides 67 Pemphigus Vulgaris 67 Omacetaxine 67 Alvine Pharmaceuticals 67 cMET 67 Early Diagnosis 67 transthyretin TTR mediated amyloidosis 67 Peripheral Blood 67 selective antagonist 67 Left Ventricular Dysfunction 67 Cyclooxygenase 2 67 Renal Cell Cancer 67 ABLYNX 67 Seasonal Influenza Vaccine 67 Expand Collaboration 67 Recommends Approval 67 IN PATIENTS WITH 67 Intravesical 67 Bevacizumab 67 Onyx Pharmaceuticals Announces 67 Carfilzomib 67 Relapsed 67 R Saizen R 67 Nat Clin Pract 67 Stem Cell Transplants 67 By JENNIFER LEARN 67 Stent Thrombosis 67 Chemoradiation 67 TRANSDUR ™ 67 Dosage Forms 67 Sign Licensing Agreement 67 MBRX 67 Genetic Variant 67 Capecitabine 67 Renal Tumors 67 evaluating picoplatin 67 developing Bicifadine serotonin 67 TRANSDUR ® 67 candidates Azedra TM 67 Carotid Stenting 67 Leukemias 67 Novel Peptide 67 Ecallantide 67 Identifies Potential 67 erlotinib Tarceva ® 67 Study Sheds Light 67 Helps Predict 67 Cyclophosphamide 67 Commercialize 67 Premature Infants 67 Organ Rejection 67 ORLive Presents 67 Begins Shipment 67 Epilepsy Drugs 67 Sustained Release 67 Antithrombin 67 Transplant Patients 67 Predict Risk 67 Thyroid Hormone 67 Antifungals 67 Enzyme Replacement Therapy 67 Preclinical Testing 67 J Am Coll 67 Urine Test 67 Entry Inhibitor 67 Vaccine Prevents 67 Androgen Deprivation Therapy 67 Enoxaparin 67 Acute Migraine 67 Double Blind Randomized 67 Allergic Rhinitis 67 TriCo Bancshares Announces 67 Genes Predict 67 Solid Tumor 67 Interferon beta 1a 67 Liver Injury 67 Aggressive Prostate Cancer 67 PPD Declares 67 Study Casts Doubt